ChromaDex Corporation (CDXC) Financial Statements (2024 and earlier)

Company Profile

Business Address 10900 WILSHIRE BLVD
LOS ANGELES, CA 90024
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments20,30028,21916,69718,81222,61645,389
Cash and cash equivalents20,30028,21916,69718,81222,61645,389
Receivables11,5825,226(1,100)2,1755,0595,338
Inventory, net of allowances, customer advances and progress billings14,67713,60111,68311,5358,2495,796
Inventory14,67713,60111,68311,5358,2495,796
Other undisclosed current assets81,8594,939996610655
Total current assets:46,56748,90532,21933,51836,53457,178
Noncurrent Assets
Operating lease, right-of-use asset3,5234,3521,226891
Property, plant and equipment   3,2063,7653,5852,872
Intangible assets, net (including goodwill)6718571,0821,3111,5471,651
Intangible assets, net (excluding goodwill)6718571,0821,3111,5471,651
Regulated entity, other noncurrent assets 6959   115
Deposits noncurrent assets     243272
Other noncurrent assets497723625762323 
Other undisclosed noncurrent assets2,7302,944   635
Total noncurrent assets:7,4908,9356,1396,7295,6985,545
TOTAL ASSETS:54,05757,84038,35840,24742,23262,724
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,01616,90415,57814,04113,8617,464
Employee-related liabilities    100
Accounts payable9,67910,4239,4459,6269,5483,718
Accrued liabilities7,3376,4816,1334,4154,3133,645
Deferred revenue157161  
Debt1620620853137310
Deferred revenue and credits131114
Due to related parties     100
Other undisclosed current liabilities680528278169311100
Total current liabilities:17,86917,61316,47615,06314,4408,088
Noncurrent Liabilities
Long-term debt and lease obligation224,1541,017866137310
Capital lease obligations137310
Finance lease, liability22 2018
Liabilities, other than long-term debt7,4944,3464,4413,873264366
Deferred revenue and credits264366
Deferred revenue3,9554,3464,4413,873
Operating lease, liability3,5394,154997848
Other undisclosed noncurrent liabilities     213126
Total noncurrent liabilities:7,5168,5005,4584,739614802
Total liabilities:25,38526,11321,93419,80215,0548,890
Equity
Equity, attributable to parent, including:28,67231,72716,42420,44527,17853,834
Common stock746862605555
Additional paid in capital214,094200,614158,190142,285116,876110,380
Accumulated deficit(185,493)(168,953)(141,825)(121,900)(89,753)(56,601)
Other undisclosed equity, attributable to parent(3)(2)(3)   
Total equity:28,67231,72716,42420,44527,17853,834
TOTAL LIABILITIES AND EQUITY:54,05757,84038,35840,24742,23262,724

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues72,05067,44959,25746,29131,55721,201
Revenue, net3,30021,201
Revenue from related parties 9,3009,3007,300 
Cost of revenue(29,253)(25,959)(23,983)(20,522)(15,502)(10,724)
Gross profit:42,79741,49035,27425,76916,05510,477
Operating expenses(61,425)(68,563)(55,128)(57,069)(49,227)(26,854)
Operating loss:(18,628)(27,073)(19,854)(31,300)(33,172)(16,377)
Nonoperating expense   (71)(847)(144)(153)
Investment income, nonoperating      5,467
Interest and debt expense  (55)(71)(847)(65)(153)
Other undisclosed income from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(18,628)(27,128)(19,996)(32,994)(33,381)(16,683)
Other undisclosed income from continuing operations before income taxes      153
Loss from continuing operations:(18,628)(27,128)(19,996)(32,994)(33,381)(16,530)
Loss before gain (loss) on sale of properties:(27,128)(19,996)(32,994)(33,381)(11,378)
Income from discontinued operations      5,152
Net loss:(18,628)(27,128)(19,996)(32,994)(33,381)(11,378)
Other undisclosed net income attributable to parent2,088 7184765 
Net loss available to common stockholders, basic:(16,540)(27,128)(19,925)(32,147)(33,316)(11,378)
Dilutive securities, effect on basic earnings per share   11,914   
Net loss available to common stockholders, diluted:(16,540)(27,128)(8,011)(32,147)(33,316)(11,378)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(18,628)(27,128)(19,996)(32,994)(33,381)(11,378)
Comprehensive loss, net of tax, attributable to parent:(18,628)(27,128)(19,996)(32,994)(33,381)(11,378)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: